VBL initiates two studies of cancer drug
The first, a Phase 2a study, will evaluate VB-111 in patients with advanced differentiated thyroid cancer (DTC), while the second trial, a Phase 1/2 trial, will evaluate VB-111
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.